Remus Pharmaceuticals Ltd

Remus Pharma. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Remus Pharmaceuticals Ltd

₹ 637 -2.30%
29 Jan - close price
remuspharma.com NSE - SME: REMUS
About

Incorporated in 2015, Remus Pharma Ltd is in the business of trading and export of API and Finished Formulations and in Technical consultancy services[1]

Key Points

Busienss Overview:[1][2]
RPL and its group of companies specialize in marketing pharmaceutical products with expertise in Critical Care, Neurology, Cardiology, and Diabetic categories, and recently getting off-patent molecules in various dosage forms and in complex generics. Company gets finished pharmaceutical formulations manufactured on loan license or contract manufacturing

Website NSE - SM
  • Market Cap ₹ 750 Cr.
  • Current Price ₹ 637
  • High / Low ₹ 1,210 / 611
  • Stock P/E 22.4
  • Book Value ₹ 261
  • Dividend Yield 0.16 %
  • ROCE 19.6 %
  • ROE 14.0 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is almost debt free.
  • Debtor days have improved from 131 to 63.6 days.
  • Company's working capital requirements have reduced from 76.0 days to 54.0 days

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Half Yearly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2023 Mar 2024 Sep 2024 Mar 2025 Sep 2025
29 185 273 348 400
20 165 252 323 373
Operating Profit 9 20 20 25 27
OPM % 32% 11% 8% 7% 7%
2 3 3 3 3
Interest 0 0 1 1 1
Depreciation 0 1 0 1 1
Profit before tax 10 22 22 25 28
Tax % 25% 15% 16% 19% 23%
6 19 19 21 22
EPS in Rs 4.87 13.16 11.87 13.57 14.85
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 TTM
213 620 748
184 575 697
Operating Profit 29 46 51
OPM % 14% 7% 7%
3 5 6
Interest 0 1 1
Depreciation 1 2 2
Profit before tax 30 47 53
Tax % 20% 19%
24 38 42
EPS in Rs 17.69 24.64 28.42
Dividend Payout % 4% 3%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 63%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 20%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: -45%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: 14%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 Sep 2025
Equity Capital 1 6 12
Reserves 156 250 295
14 23 16
161 154 245
Total Liabilities 333 433 568
14 16 18
CWIP 0 0 0
Investments 105 186 238
215 231 313
Total Assets 333 433 568

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025
1 7
-25 -11
28 6
Net Cash Flow 4 3

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025
Debtor Days 198 64
Inventory Days 96 35
Days Payable 209 49
Cash Conversion Cycle 85 50
Working Capital Days 98 54
ROCE % 20%

Shareholding Pattern

Numbers in percentages

5 Recently
Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Sep 2025
69.61% 70.60% 70.66% 70.84% 70.85% 70.91%
2.38% 3.25% 3.00% 3.16% 4.77% 5.02%
0.71% 0.67% 0.73% 0.77% 0.77% 0.77%
27.30% 25.49% 25.61% 25.22% 23.60% 23.31%
No. of Shareholders 8561,1241,5771,7531,8782,032

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls